Jurnalul de chirurgie
Aparitie trimestriala in a doua luna a trimestrului
Published quarterly in the second month of the quarter ISSN: 1584 - 9341
Vol.10 Nr.3 - Iulie-Septembrie 2014 | s�mb�t�, 23 martie 2019
ISSN: 1584 - 9341 Vol.10 No.3 - July-September 2014
English| Romana
Creditare EMC Colegiul Medicilor
Syndicate
IMMUNOTHERAPY WITH VISCUM ALBUM EXTRACT IN THE TREATMENT OF ADVANCED COLORECTAL CANCER T. Oniu, M. Cazacu, V. Muntean, Melania Oniu, Anca Mihailov, C. Lungoci Surgery Clinic IV “Iuliu Hațieganu” University of Medicine and Pharmacy Cluj-Napoca Jurnalul de chirurgie 2011; 7 (4): 636-653 Full text: Format PDF (Română/Romanian)
Abstract:
Background: Most clinical trials using mistletoe to treat colorectal cancer are out-of-date and have major methodological weaknesses that raise doubts about their findings. Meanwhile, the arsenal of chemotherapy has much evolved over the last decade. Thus, the aim of this study was to determine the effectiveness of the total plant extract Isorel in association with modern chemotherapy in the treatment of colorectal cancer. Methods: After the surgical removal of the primary tumor, a total of 124 patients with advanced colorectal cancer (stage Dukes C and D), were randomly divided into the immunotherapy group (Isorel associated in most of the cases with chemotherapy, n=58) and the control group (most of which received chemotherapy). The chemotherapy regimens were based on 5-fluorouracil, irinotecan and oxaliplatin. Overall survival and adverse events were observed. Results: The addition of immunotherapy with Viscum album extract Isorel to 5FU-based chemotherapy significantly improved overall survival in Dukes stage C (5-year survival: 46% vs. 17%; median survival: 46 vs. 24 months, p=0.004) and D (median survival: 13,5 vs. 9,5 months, p=0.02; longest survival: 26 vs. 12 months). The addition of immunotherapy to oxaliplatin- and irinotecan-based chemotherapy further improved overall survival in Dukes stage C (5-year survival: 64% vs. 38%; median survival: 57,5 vs. 34 months, p=0.04) and D (median survival: 24 vs. 18 months, p=0.02; longest survival: 36 vs. 24 months). Inflammatory local reactions at the s.c. injection site occur frequently (83% of patients) at the beginning of the treatment for 1 to 8 weeks. Conclusions: Immunotherapy with Viscum album extract Isorel, added to chemotherapy, improves the survival of the patients operated for advanced colorectal cancer compared with chemotherapy alone, whatever its type.
| Romana 
